ABSTRACT BACKGROUND Non-vitamin K antagonist oral anticoagulants (NOACs) are relatively new drugs used for stroke
from case reports and pharmacovigilance analyses of a possible hepatotoxic risk associated with the use of NOACs (3, 4) . Moreover, all NOACs have been associated with transaminase elevations (5) (6) (7) . In addition, ximelagatran, a Factor IIa inhibitor, failed to obtain marketing authorization due to concerns over hepatic adverse events (8, 9) . Thus, current guidelines by the European Society of Cardiology on the use of NOACs recommend annual monitoring of liver function (10) .
To date, 1 observational study has assessed the risk of liver injury associated with the use of NOACs, showing a decreased risk when compared with VKAs (11) . However, it is unclear whether these findings are the result of methodological limitations, such as channeling of the comparator drug class (i.e., VKAs) to high-risk patients, or information bias (12) . Moreover, because the study population comprised a mix of patients with and without prior liver disease, no inferences can be drawn regarding hepatotoxicity according to baseline liver status. Therefore, further studies are needed to address this important safety question.
Thus, the objective of this population-based study was to determine whether the use of NOACs is associated with an increased risk of serious liver injury compared with the use of VKAs in NVAF patients with and without prior liver disease. OUTCOME. The outcome of interest was serious liver injury, defined as hospitalization with liver injury or death due to liver injury, using the respective ICD-10 codes (K71, K72, K74.6, K75.9, K76.2, K76.9, Z944) in the MEDÉCHO (anywhere in the hospitalization record) and the ISQ (as the underlying cause of death).
METHODS
Codes from the International Classification of Diseases classification system have been successfully used to assess adverse hepatic outcomes in the past (20,21).
COVARIATES. All models were adjusted for risk factors known to be associated with liver injury and that might also influence the decision to initiate treatment with oral anticoagulants. Demographic characteristics were measured at cohort entry and consisted of age, sex, and year of cohort entry. Age was modeled flexibly as a continuous variable using restricted cubic splines with 5 interior knots to account for a potentially nonlinear relationship with the outcome (22) .
The models were also adjusted for congestive heart failure, dyslipidemia, and diabetes mellitus recorded at any time before cohort entry, because these conditions have been associated with liver disease (23, 24) . Moreover, we adjusted for use of acetaminophen in the year prior to cohort entry, because acetaminophen-related hepatotoxicity is the most common cause of drug-induced liver injury, and the prevalence of its use in our cohort was high ( Values are n, mean AE SD, or n (%). *Measured within the first 3 months after cohort entry. VKAs. Moreover, they were more likely to have entered the cohort in the last 2 years of the study period. Douros et al.
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this stricter outcome definition analysis was based on few exposed events. (38) . Second, the population-based setting and the few exclusion criteria applied during the formation of our study cohort make the results of this study highly generalizable.
Our study also has some limitations. First, because the RAMQ does not contain laboratory values, our outcome definition was based only on ICD-10 codes and we could not consider liver enzyme elevations.
Although this may have reduced the sensitivity of our outcome definition, we included only cases of liver injury requiring hospitalization or leading to death, which are more likely to be valid in databases (39) .
Therefore, we do not expect any substantial misclassification of the outcome. Second, given the observational nature of the study, residual confounding is possible. In particular, channeling of high-risk patients to VKAs could be a source of bias.
Indeed, VKA patients were older and had a higher prevalence of hepatotoxic risk factors at baseline. To mitigate this potential limitation, we stratified patients based on liver status at baseline and adjusted for well-established potential confounders. Moreover, we conducted several sensitivity analyses, such as adjusting for 16 additional covariates, using disease risk score and propensity score as alternate means to control for confounding, and using a marginal structural Cox proportional hazards model to assess potential time-varying confounding; these analyses led to results consistent with those of the primary analysis. Finally, due to the relatively small size of the subcohort with prior liver disease, we cannot exclude a decreased risk of serious liver injury associated with the use of NOACs in this population.
Moreover, the effect estimates for specific NOACs, and especially for the 2 Factor Xa inhibitors rivaroxaban and apixaban, require replication due to the low number of exposed events. Canada. E-mail: christel.renoux@mcgill.ca.
CONCLUSIONS
PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE:
In patients with newly identified atrial fibrillation, target-specific oral anticoagulants are associated with no greater risk of liver injury than VKAs, independent of antecedent liver disease. 
